Cargando…
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs
The incidence of second primary malignancies (SPM) in long-term survivors of multiple myeloma (MM) is increasing because of increased life expectancy. We retrospectively analyzed the risk factors for SPM in patients with MM after autologous stem cell transplantation (ASCT) before and after the intro...
Autores principales: | Takamatsu, Hiroyuki, Matsuda, Tomohiro, Mizuno, Shohei, Takahashi, Tsutomu, Fuchida, Shin-ichi, Hanamura, Ichiro, Kataoka, Keisuke, Tsukada, Nobuhiro, Matsumoto, Morio, Hangaishi, Akira, Doki, Noriko, Uchida, Naoyuki, Sawa, Masashi, Maruyama, Yumiko, Kurahashi, Shingo, Nagafuji, Koji, Harazaki, Yoriko, Kako, Shinichi, Iida, Shinsuke, Ichinohe, Tatsuo, Kanda, Yoshinobu, Atsuta, Yoshiko, Sunami, Kazutaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690906/ https://www.ncbi.nlm.nih.gov/pubmed/37470160 http://dx.doi.org/10.3324/haematol.2023.283202 |
Ejemplares similares
-
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan
por: Miyamoto‐Nagai, Yurie, et al.
Publicado: (2022) -
Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum
por: Nakaya, Aya, et al.
Publicado: (2021) -
Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine
por: Shimazu, Yutaka, et al.
Publicado: (2021) -
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment
por: Soncini, Debora, et al.
Publicado: (2021) -
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)